Viking Therapeutics to Present at Upcoming Investor Conferences
Viking Therapeutics (NASDAQ: VKTX) announced their participation in two investor conferences: the 34th Annual Roth Conference from March 13-15, 2022, and the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. CEO Brian Lian will engage in a fireside chat and management will hold one-on-one meetings at Roth. At Oppenheimer, Lian will present on March 16 at 11:40 a.m. Pacific. The Oppenheimer presentation will be available via webcast. Viking focuses on developing therapies for metabolic disorders, including VK2809 for NASH and fibrosis.
- None.
- None.
SAN DIEGO, March 8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will present at two upcoming investor conferences.
Details of the company's participation are as follows:
- 34th Annual Roth Conference
Details: Brian Lian, Ph.D., chief executive officer of Viking, will participate in a fireside chat and Viking management will participate in 1-on-1 meetings
Conference Dates: March 13-15, 2022
Fireside Chat Time: 9:00 a.m. Pacific on Tuesday, March 15, 2022
Format: Hybrid conference with both in-person and virtual participation - Oppenheimer 32nd Annual Healthcare Conference
Details: Dr. Lian will deliver a corporate presentation and Viking management will participate in 1-on-1 meetings
Conference Dates: March 15-17, 2022
Presentation Time: 11:40 a.m. Pacific on Wednesday, March 16, 2022
Format: Virtual conference; webcast available
A live webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company's third clinical candidate is VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-upcoming-investor-conferences-301497127.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics present at the 34th Annual Roth Conference?
What is the schedule for Viking Therapeutics at the Oppenheimer Healthcare Conference?
Where can I watch the Viking Therapeutics presentation from the Oppenheimer conference?
What therapies is Viking Therapeutics developing?
